Comparing Solifenacin, Tolterodine, and Fesoterodine in Patients with Ureteral Stent Related Symptoms: Evidencefrom a Randomized Controlled Trial - nil

Start Date01 Apr 2025

Sponsor / Collaborator

Sanjay Gandhi Post Graduate Institute of Medical Sciences

CTR20231909

/ CompletedPhase 3

评价富马酸非索罗定缓释片用于膀胱过度活动症患者的有效性和安全性的随机、双盲、安慰剂对照、多中心临床试验

[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of fesoterodine fumarate extended-release tablets in patients with overactive bladder

评价富马酸非索罗定缓释片用于膀胱过度活动症患者的有效性和安全性

[Translation]

To evaluate the efficacy and safety of fesoterodine fumarate extended-release tablets in patients with overactive bladder

Start Date25 Aug 2023

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

[+1]

CTR20220830

/ RecruitingNot Applicable

评估受试制剂富马酸非索罗定缓释片（规格：8 mg）与参比制剂（Toviaz®）（规格：8 mg）在中国健康受试者中空腹和餐后状态下的单中心、开放、随机、单剂量、两周期、双交叉生物等效性研究

[Translation] A single-center, open-label, randomized, single-dose, two-period, double-crossover bioequivalence study to evaluate the bioequivalence of the test formulation, fesoterodine fumarate extended-release tablets (strength: 8 mg), and the reference formulation (Toviaz®) (strength: 8 mg) in healthy Chinese subjects under fasting and fed conditions

主要研究目的以江苏万邦生化医药集团有限责任公司研制的富马酸非索罗定缓释片（规格：8mg）为受试制剂，按生物等效性研究的有关规定，与Pfizer Europe MA EEIG持证、Pfizer Manufacturing Deutschland GmbH生产的富马酸非索罗定缓释片（参比制剂，商品名：Toviaz®，规格：8 mg）对比在健康人体内的药代动力学特征，考察两制剂的人体生物等效性。次要研究目的考察富马酸非索罗定缓释片受试制剂（规格：8 mg）和参比制剂（商品名：Toviaz®，规格：8 mg）在健康受试者中的安全性。

[Translation]

Main research purpose Using fesoterodine fumarate sustained-release tablets (specification: 8 mg) developed by Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. as the test preparation, according to the relevant provisions of bioequivalence studies, the pharmacokinetic characteristics in healthy humans were compared with fesoterodine fumarate sustained-release tablets (reference preparation, trade name: Toviaz®, specification: 8 mg) certified by Pfizer Europe MA EEIG and produced by Pfizer Manufacturing Deutschland GmbH, to investigate the bioequivalence of the two preparations in humans. Secondary research purpose Investigate the safety of fesoterodine fumarate sustained-release tablets (specification: 8 mg) and reference preparations (trade name: Toviaz®, specification: 8 mg) in healthy subjects.

Start Date20 Feb 2022

Sponsor / Collaborator

Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with Fesoterodine Fumarate

100 Translational Medicine associated with Fesoterodine Fumarate

100 Patents (Medical) associated with Fesoterodine Fumarate

416

Literatures (Medical) associated with Fesoterodine Fumarate

01 Nov 2025·BURNS

Antimuscarinics for burn patients: Helpful or harmful for sensation recovery?

Article

Author: Khong, Jeffrey ; Zamore, Zachary H ; Lerman, Sheera F ; Park, Kitae Eric ; McCaffrey, Tara ; Caffrey, Julie A ; Niknejad, Keon ; Kuo, Keith T ; Tuffaha, Sami ; Suresh, Rachana

BACKGROUND:

Burn injuries are a major cause of morbidity and mortality, often resulting in nerve damage that causes pain or numbness. Loss of protective sensation increases the risk of future injury. Enhancing nerve regeneration after burns is critical. Antimuscarinic drugs, used to treat overactive bladder, have shown potential in promoting peripheral nerve growth by supporting cytoskeletal development and mitochondrial trafficking. This study investigates whether antimuscarinic use at the time of burn injury is associated with increased nerve regeneration.

METHODS:

We conducted a retrospective analysis using the TriNetX Research Database. Burn patients were identified using ICD-10-CM codes by anatomical area and total burn surface area (TBSA). The experimental group included patients taking one of seven antimuscarinic drugs (darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine, or trospium) at the time of injury. Controls were burn patients not on these medications. Patients with preexisting sensory disturbances were excluded. Propensity score matching was performed by age, sex, diabetes status, and either burn location or TBSA. Paresthesia 3-24 months post-injury was used as a proxy for nerve regeneration.

RESULTS:

Among 362,224 patients with burns coded by anatomical area, 9266 antimuscarinic users were matched to 9266 controls. Users were over twice as likely to develop paresthesia (RR: 2.19, CI: [1.85, 2.60]) and had higher analgesic use (52.4 % vs. 30.3 %, p < 0.001). For 168,164 patients with burns coded by TBSA, 3294 matched pairs showed similar findings: increased paresthesia (RR: 2.95, CI: [2.06, 4.23]) and analgesic use (50.1 % vs. 25.3 %, p < 0.001).

CONCLUSION:

Burn patients on antimuscarinic therapy were more likely to develop paresthesia, possibly indicating nerve regeneration. While this may reflect sensory recovery, it could also lead to abnormal or painful sensations that negatively impact quality of life. Further research is needed to assess functional outcomes.

01 Nov 2025·NEUROUROLOGY AND URODYNAMICS

Comparison of the Efficacy of Vibegron and Fesoterodine for Neurogenic Detrusor Overactivity in Individuals With Spinal Cord Lesion: A Single‐Center Prospective Randomized Crossover Trial

Article

Author: Takahashi, Ryosuke ; Imada, Kenjiro ; Maki, Tomoko

ABSTRACT:

Introduction:

To compare the efficacy of the β3 agonist vibegron and the anticholinergic agent fesoterodine in the management of neurogenic detrusor overactivity (NDO) in individuals with spinal cord lesion (SCL).

Materials and Methods:

This was a single‐center, prospective, open‐label, randomized, crossover study. A total of 41 individuals with SCL undergoing clean intermittent catheterization, who required pharmacological treatment for NDO confirmed by cystometrogram (CMG), were enrolled in the study. Most patients were < 6 months from SCL. Patients were randomly assigned to receive either vibegron (50 mg) or fesoterodine (4 mg) in a crossover design for 4 weeks each, with no washout period between treatments. The efficacy of the two medications was evaluated during the first 4 weeks using CMG parameters and the International Consultation on Incontinence Questionnaire‐Short Form (ICIQ‐SF). At the end of the second 4‐week period, participants were surveyed on their preference for the continuation of either drug, based on efficacy, adverse events, and overall satisfaction.

Results:

During the first 4 weeks, CMG parameters, including detrusor pressure and cystometric capacity, significantly improved in both groups, with no significant differences observed between the groups. The ICIQ‐SF scores also demonstrated significant improvements in almost all items in both groups; however, the improvements in Q3 (Overall impact of UI) and the total score were significantly better in the vibegron group. At the end of the second 4‐week period, participant survey results indicated that 58% preferred vibegron, 6% preferred fesoterodine, and 36% rated both as equivalent for future continuation therapy.

Conclusion:

Vibegron significantly improved CMG parameters in addition to alleviating UI symptoms, demonstrating efficacy that was not inferior to that of fesoterodine. With a lower incidence of adverse events and high patient satisfaction, vibegron may serve as a useful therapeutic option for the treatment of NDO in individuals with SCL.

01 Sep 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database

Article

Author: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Hu, Jiaoyue ; Guan, Wen-Ying ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu

BACKGROUND:

Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.

METHODS:

We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.

RESULTS:

Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.

CONCLUSION:

Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.

News (Medical) associated with Fesoterodine Fumarate

14 Oct 2025

·www.drugtopics.com

White House Strikes Deal with Pfizer for Lower Drug Prices, Online DTC Website

Amid ongoing approaches to lower drug prices for US patients, like the Most-Favored-Nation policy, this is another partnership the Trump Administration believes will improve access challenges. The Trump Administration is set to team up with Pfizer in a partnership that would bring lower prices for the manufacturer’s drugs as well as a direct-to-consumer (DTC) website for patients to purchase them, which the White House is naming “TrumpRx.”1 While the rollout of this new partnership is still in its beginning stages, Pfizer is the first drugmaker to provide actionable steps in lowering US drug prices across the board,2 an initiative perpetuated by the signing of the Most-Favored-Nation (MFN) Prescription Drug Pricing Executive Order.3 “It’s a win for American patients, a win for American leadership, and it’s a win for Pfizer because it provides the certainty and stability we need to continue advancing new breakthrough medicines for patients,” said Pfizer spokeswoman Amy Rose, according to The Wall Street Journal.2 Despite early reports of the Pfizer program providing a decrease in drug prices for Medicaid patients, there is potential for savings to reach the pockets of all US patients and consumers as President Trump continues to put pressure on manufacturers. On top of this most recent Pfizer-White House partnership, as well as provisions backed by the MFN policy, the potential impact of pharmaceutical tariffs could add a third layer to the evolution of drug prices in the US. With the new partnership, Pfizer will receive a 3-year grace period on being susceptible to Trump’s pharmaceutical tariffs, which are expected to take effect October 1. “The agreement on lower prices will cover ‘a large majority’ of Pfizer's primary care medicines, along with specialty brand-name drugs, which will be offered at discounts averaging 50% and reaching as high as 85%, a spokesperson for the company said,” according to NBC News.1 Some of the drugs correspondents close to the partnership have named for future price reductions include the menopause medication Duavee (conjugated estrogens/bazedoxifene), Toviaz (fesoterodine fumarate) for treating overactive bladder, and Pfizer’s Eucrisa (crisaborole) skin ointment.4-6 On top of these, and whatever additional drugs that Pfizer already markets, all new drugs that the company introduces will also be sold at lower prices.1 Alongside the announcement of this unprecedented partnership, the administration is set to roll out its “TrumpRx” DTC website for patients across the country to access necessary prescription medications. The website will be fully owned and operated by the US government as well as giving it the federal power to negotiate the prices of DTC drugs themselves.2 The extent of which drugs will be offered and at what type of discounts through the TrumpRx website is currently unknown. There is also uncertainty regarding what patient populations and insurance coverage would be set aside to reap the benefits of these discounts and savings. However, according to Pfizer and White House spokespeople who reported to The Wall Street Journal, the new partnership is projected to benefit as many as 100 million US patients. “Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations,” said Trump, according to Politico.7 Amid the administration’s ongoing commitment to lower US drug prices, they are looking to get US consumers on a level playing field with consumers in other, developed nations. Hence, the MFN drug policy; this was signed as an executive order in June of this year and plainly states that multiple federal agencies should “take specific actions aimed at compelling drug manufacturers to lower drug prices in the United States in a manner comparable with other ‘developed nations.’”3 From the MFN drug policy to prospective pharmaceutical tariffs and a key partnership between the federal government and a major US drug manufacturer, there is significant movement from the Trump Administration to recorrect the rate of rising drug costs in the US. Many experts in the pharmacy and pharmaceutical industry have expressed disagreement and uncertainty regarding the aforementioned provisions, partnerships, and policies. However, with the continued fight stemming from the administration’s goal to lower drug prices, patients can be hopeful for discounted savings as these programs roll out.1 “President Trump is leveraging the power of the federal government to drastically cut drug prices for everyday Americans,” concluded White House spokesman Kush Desai, according to The Wall Street Journal.2 “Democrats talked the talk for decades about drug prices, but only President Trump is actually walking the walk.” The content above comes from the network. if any infringement, please contact us to modify.

Innovative Drug

08 Jul 2022

·www.biospace.com

Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market

HYDERABAD, India &PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy's Laboratories, Inc. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announces the launch of Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine fumarate) Extended-Release Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA). The Toviaz® brand had U.S. sales of approximately $211 million MAT for the most recent twelve months ending in May 2022 according to IQVIA. Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30. Please click here to see the full prescribing information: . Toviaz is a trademark of Pfizer Inc. RDY-0622-424 About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.

Generic DrugBiosimilarAcquisition

29 Jun 2022

·www.prnewswire.com

Interstitial Cystitis Drugs Market Recorded 4.81% Y-O-Y Growth Rate in 2021| Evolving Opportunities with Perrigo Co. Plc & Pfizer Inc | Technavio

NEW YORK, June 29, 2022 /PRNewswire/ -- The Interstitial Cystitis Drugs Market report provides a detailed analysis of the competitive scenario, the pre-and post-COVID-19 impact on businesses, and the market growth across various regions. The interstitial cystitis drugs market size is expected to increase by USD 283.95 million, at a CAGR of 5.06% from 2020 to 2025. Technavio categorizes the interstitial cystitis drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the interstitial cystitis drugs market during the forecast period. Technavio has announced its latest market research report titled Interstitial Cystitis Drugs Market by Type and Geography - Forecast and Analysis 2021-2025 For more highlights on the parent market analysis - Request a sample now! Market Dynamics Drivers: The high prevalence of interstitial cystitis is notably driving the interstitial cystitis drugs market growth Trends: Increasing awareness of interstitial cystitis is the key market trend driving the interstitial cystitis drugs market growth. Challenges: The major challenge impeding the interstitial cystitis drugs market growth is the lack of approved drugs. For detailed highlights on the market dynamics - Click Now! Segmentation Analysis By Type, the market is classified into oral therapy and intravesical therapy. The interstitial cystitis drugs market share growth by the oral therapy segment will be significant for revenue generation. Pentosan polysulfate sodium (ELMIRON) is the only approved oral medication to repair the lining of the bladder in people with interstitial cystitis (IC). ELMIRON builds and restores the protective coating of the bladder tissue. There are many off-label oral drugs in the interstitial cystitis drugs market that can reduce the signs and symptoms of the disease facilitating the growth of the segment during the forecast period. By Geography, the market is classified as North America, Europe, Asia, and ROW. 36% of the market's growth will originate from North America during the forecast period. The US is a key market for interstitial cystitis drugs in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia and Europe. The increasing cases of interstitial cystitis and a rise in research funding will facilitate the interstitial cystitis drugs market growth in North America over the forecast period. Company Profiles The interstitial cystitis drugs market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The interstitial cystitis drugs market report provides complete insights on key vendors including Astellas Pharma Inc., Bayer AG, Johnson and Johnson Inc., Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Key Offerings: Perrigo Co. Plc - The company offers pain and sleep aids such as Ibuprofen. Pfizer Inc. - The company offers an interstitial cystitis drug named Toviaz. Seikagaku Corp. - The company is developing the interstitial cystitis and bladder pain syndrome drug SI-722. Sun Pharmaceutical Industries Ltd. - The company offers interstitial cystitis drugs such as Cystopen capsules Teva Pharmaceutical Industries Ltd. The company offers interstitial cystitis drugs such as VESIcare (solifenacin succinate) Tablets. To know about all major vendor offerings - Grab a sample now! Get ready to achieve excellent business outcomes from this exclusive Interstitial Cystitis Drugs Market report by Technavio. The report will include highlights of the overall market which includes frequently asked questions such as - What are historical revenue figures and estimated revenue figures as well as CAGR during the forecast timeframe? What is the current trend taking place in the market space? Which are business tactics that will influence competitive scenarios along with defining the growth potential of the market? What are market drivers, restraints, and challenges impacting demand & growth of the market? Which regions & segments will garner massive revenue and emerge as market leaders in upcoming years? The competitive scenario provided in the Interstitial Cystitis Drugs Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Don't wait, Make a strategic approach & boost your business goals with our Interstitial Cystitis Drugs Market Forecast Report - Buy Now! Related Reports: The uveitis drugs market share is expected to increase to USD 269.65 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.9%. The vitiligo therapeutics market share is expected to increase to USD 341.35 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.5%. Table of Content 1 Executive Summary 2 Market Landscape 2.1 Market ecosystem Exhibit 01: Parent market Exhibit 02: Market characteristics 2.2 Value chain analysis Exhibit 03: Value chain analysis: Pharmaceuticals 3 Market Sizing 3.1 Market definition Exhibit 04: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 05: Market segments 3.3 Market size 2020 3.4 Market outlook: Forecast for 2020 - 2025 Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million) Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 08: Five forces analysis 2020 & 2025 4.2 Bargaining power of buyers Exhibit 09: Bargaining power of buyers 4.3 Bargaining power of suppliers Exhibit 10: Bargaining power of suppliers 4.4 Threat of new entrants Exhibit 11: Threat of new entrants 4.5 Threat of substitutes Exhibit 12: Threat of substitutes 4.6 Threat of rivalry Exhibit 13: Threat of rivalry 4.7 Market condition Exhibit 14: Market condition - Five forces 2020 5 Market Segmentation by Type 5.1 Market segments Exhibit 15: Type - Market share 2020-2025 (%) 5.2 Comparison by Type Exhibit 16: Comparison by Type 5.3 Oral therapy - Market size and forecast 2020-2025 Exhibit 17: Oral therapy - Market size and forecast 2020-2025 ($ million) Exhibit 18: Oral therapy - Year-over-year growth 2020-2025 (%) 5.4 Intravesical therapy - Market size and forecast 2020-2025 Exhibit 19: Intravesical therapy - Market size and forecast 2020-2025 ($ million) Exhibit 20: Intravesical therapy - Year-over-year growth 2020-2025 (%) 5.5 Market opportunity by Type Exhibit 21: Market opportunity by Type 6 Customer landscape 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 23: Market share by geography 2020-2025 (%) 7.2 Geographic comparison Exhibit 24: Geographic comparison 7.3 North America - Market size and forecast 2020-2025 Exhibit 25: North America - Market size and forecast 2020-2025 ($ million) Exhibit 26: North America - Year-over-year growth 2020-2025 (%) 7.4 Europe - Market size and forecast 2020-2025 Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million) Exhibit 28: Europe - Year-over-year growth 2020-2025 (%) 7.5 Asia - Market size and forecast 2020-2025 Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million) Exhibit 30: Asia - Year-over-year growth 2020-2025 (%) 7.6 ROW - Market size and forecast 2020-2025 Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million) Exhibit 32: ROW - Year-over-year growth 2020-2025 (%) 7.7 Key leading countries Exhibit 33: Key leading countries 7.8 Market opportunity by geography Exhibit 34: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges Exhibit 35: Impact of drivers and challenges 8.3 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 36: Vendor landscape 9.3 Landscape disruption Exhibit 37: Landscape disruption Exhibit 38: Industry risks 10 Vendor Analysis 10.1 Vendors covered Exhibit 39: Vendors covered 10.2 Market positioning of vendors Exhibit 40: Market positioning of vendors 10.3 Astellas Pharma Inc. Exhibit 41: Astellas Pharma Inc. - Overview Exhibit 42: Astellas Pharma Inc. - Product and service Exhibit 43: Astellas Pharma Inc. - Key news Exhibit 44: Astellas Pharma Inc. - Key offerings 10.4 Bayer AG Exhibit 45: Bayer AG - Overview Exhibit 46: Bayer AG - Business segments Exhibit 47: Bayer AG - Key news Exhibit 48: Bayer AG - Key offerings Exhibit 49: Bayer AG - Segment focus 10.5 Johnson and Johnson Inc. Exhibit 50: Johnson and Johnson Inc. - Overview Exhibit 51: Johnson and Johnson Inc. - Business segments Exhibit 52: Johnson and Johnson Inc. - Key news Exhibit 53: Johnson and Johnson Inc. - Key offerings Exhibit 54: Johnson and Johnson Inc. - Segment focus 10.6 Novartis AG Exhibit 55: Novartis AG - Overview Exhibit 56: Novartis AG - Business segments Exhibit 57: Novartis AG - Key news Exhibit 58: Novartis AG - Key offerings Exhibit 59: Novartis AG - Segment focus 10.7 Perrigo Co. Plc Exhibit 60: Perrigo Co. Plc - Overview Exhibit 61: Perrigo Co. Plc - Business segments Exhibit 62: Perrigo Co. Plc - Key news Exhibit 63: Perrigo Co. Plc - Key offerings Exhibit 64: Perrigo Co. Plc - Segment focus 10.8 Pfizer Inc. 10.9 Seikagaku Corp. Exhibit 69: Seikagaku Corp. - Overview Exhibit 70: Seikagaku Corp. - Business segments Exhibit 71: Seikagaku Corp. - Key offerings Exhibit 72: Seikagaku Corp. - Segment focus 10.10 Sun Pharmaceutical Industries Ltd. Exhibit 73: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 74: Sun Pharmaceutical Industries Ltd. - Product and service Exhibit 75: Sun Pharmaceutical Industries Ltd. - Key news Exhibit 76: Sun Pharmaceutical Industries Ltd. - Key offerings 10.11 Teva Pharmaceutical Industries Ltd. Exhibit 77: Teva Pharmaceutical Industries Ltd. - Overview Exhibit 78: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 79: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 80: Teva Pharmaceutical Industries Ltd. - Segment focus 10.12 Viatris Inc. Exhibit 81: Viatris Inc. - Overview Exhibit 82: Viatris Inc. - Business segments Exhibit 83: Viatris Inc. - Key offerings Exhibit 84: Viatris Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Currency conversion rates for US$ Exhibit 85: Currency conversion rates for US$ 11.3 Research methodology Exhibit 86: Research Methodology Exhibit 87: Validation techniques employed for market sizing Exhibit 88: Information sources 11.4 List of abbreviations Exhibit 89: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

100 Deals associated with Fesoterodine Fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
D08923	Fesoterodine Fumarate	G04BD11	DB06702

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Urinary Bladder, Neurogenic	Japan	Pfizer Japan, Inc.	26 Sep 2022
Neurogenic detrusor overactivity	United States	Pfizer Inc.	17 Jun 2021
Urinary Incontinence, Urge	Japan	Pfizer Japan, Inc.	25 Dec 2012
Urinary Bladder, Overactive	United States	Pfizer Inc.	31 Oct 2008
Overactive bladder syndrome	European Union	Pfizer Europe MA EEIG	20 Apr 2007
Overactive bladder syndrome	Iceland	Pfizer Europe MA EEIG	20 Apr 2007
Overactive bladder syndrome	Liechtenstein	Pfizer Europe MA EEIG	20 Apr 2007
Overactive bladder syndrome	Norway	Pfizer Europe MA EEIG	20 Apr 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pollakisuria	Phase 3	China	Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.	25 Aug 2023
Pollakisuria	Phase 3	China	Cisen Pharmaceutical Ltd.	25 Aug 2023
Urinary urgency	Phase 3	China	Cisen Pharmaceutical Ltd.	25 Aug 2023
Urinary urgency	Phase 3	China	Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.	25 Aug 2023
Brain Diseases	Phase 3	United States	Pfizer Inc.	02 Jul 2012
Brain Diseases	Phase 3	Japan	Pfizer Inc.	02 Jul 2012
Brain Diseases	Phase 3	Belgium	Pfizer Inc.	02 Jul 2012
Brain Diseases	Phase 3	Canada	Pfizer Inc.	02 Jul 2012
Brain Diseases	Phase 3	Estonia	Pfizer Inc.	02 Jul 2012
Brain Diseases	Phase 3	Finland	Pfizer Inc.	02 Jul 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04090190 (CTgov)	Phase 4	Inflammation \| Urinary Incontinence, Urge	20	Oxybutynin+Tolterodine+Trospium+Solifenacin+Fesoterodine	afaugcnlua(xwtdnxqtqr) = ydzjzqqsil iemqcmbsxn (bjuetjmrnf, fqekfrdlvk - uljblskkur) View more	-	03 Oct 2022
NCT03946124 (Pubmed \| Female Pelvic Med Reconstr Surg)	Phase 4	Urinary Bladder, Overactive	75	Fesoterodine	bzfcqxbjwc(aoqqhgwimo) = fopxlpepnw jtuuhsgppt (flydgbopej )	-	01 Dec 2021
NCT02501928 (CTgov)	Phase 3	Urinary Bladder, Neurogenic \| Neurogenic detrusor overactivity \| Urinary Bladder, Overactive	12	fesoterodine (Cohort 1)	ieobrqqotz = uyfjmactlu ddnjamowbb (epxkejjizr, dqaocehpru - dtlzkulqka) View more	-	26 Oct 2020
NCT02501928 (CTgov)	Phase 3		12	fesoterodine (Cohort 2)	ieobrqqotz = jaxshayvda ddnjamowbb (epxkejjizr, zgtisgrgpm - kbuxfeaqcl) View more	-	26 Oct 2020
NCT03946124 (CTgov)	Phase 4	Urinary Bladder, Overactive	74	Fesoterodine	enpzuvaqzn(jjjsesahog) = wjeoxbfrlt rstkkcrpnk (rjufgrybfx, xadhptzbzb - lttmpxvzpy) View more	-	11 Dec 2019
AUA2019	Phase 2	Neurogenic detrusor overactivity	10	Fesoterodine	mkerrgdkab(dtnrlaxwvj) = zogkmdsfpb bcrrrpajta (crllqkvsqq ) View more	-	01 Apr 2019
NCT00605319 (Toviaz, CTgov)	Phase 4	Prostatic Hyperplasia \| Urinary Bladder Neck Obstruction \| Urinary Bladder, Overactive	17	Toviaz	ugirymuekh(bzcioxskgm) = ngnebfccyq mrwzlnwxkh (avdmcibdlo, ybtwrueqao - zleeffghoc) View more	-	10 Apr 2018
NCT01367886 (CTgov)	Not Applicable	Urinary Bladder, Overactive	21	fesoterodine	mfrdopxbgd(vygfttowct) = aaloalvcfj ywdbnlugiy (geifaqzbko, 4.88) View more	-	12 Jan 2015
NCT01605617 (CTgov)	Phase 4	Urinary Bladder, Overactive	4	PTNS+Fesoterodine Fumarate (While on PTNS + Fesoterodine Fumarate First)	ocjjyuqkax(lnyqarjjsv) = lmrfibpzzk mwkefdzupz (bvbvpsdmbi, hlcptpepwa - bnwtqdjwcf) View more	-	05 Feb 2014
NCT01605617 (CTgov)	Phase 4	Urinary Bladder, Overactive	4	PTNS (While on PTNS + Placebo First)	ocjjyuqkax(lnyqarjjsv) = qicssxtsql mwkefdzupz (bvbvpsdmbi, ypyyykekjx - cnhenjlwwn) View more	-	05 Feb 2014
NCT00928070 (Pubmed \| J Urol)	Phase 4	Urinary Incontinence	562	Fesoterodine	omrhsctvmr(verclquikt) = awiuzorzte mebiwerujt (hjaewhjznb )	Positive	01 Feb 2014
NCT00928070 (Pubmed \| J Urol)	Phase 4	Urinary Incontinence	562	Placebo	omrhsctvmr(verclquikt) = bheeucfyck mebiwerujt (hjaewhjznb )	Positive	01 Feb 2014
NCT00798434 (SOFIA, Pubmed \| Neurourol Urodyn)	Phase 4	Urinary Bladder, Overactive	-	Fesoterodine 4 mg	gpzinlvdxc(hpywwnqnjd) = tamhrylgkg osxlryufrz (ecprwpxclp ) View more	Positive	01 Jan 2014
NCT00798434 (SOFIA, Pubmed \| Neurourol Urodyn)	Phase 4	Urinary Bladder, Overactive	-	Placebo	gpzinlvdxc(hpywwnqnjd) = ldvwkklfuw osxlryufrz (ecprwpxclp ) View more	Positive	01 Jan 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis